Home » Topics » Conferences, BioWorld Science

Conferences, BioWorld Science
RSS

Unique agent for cognition disorders: GTS-21, a nicotinic acetylcholine agonist

Aug. 17, 1998

Combination therapy with naltrexone, TA-0910 and fluoxetine is an effective treatment for alcoholism

Aug. 17, 1998

First volunteers dosed with R.W. Johnson's new gpIIb/IIIa antagonist

Aug. 14, 1998

Muscle-relaxant activity of silperisone: comparison with lidocaine

Aug. 14, 1998

Analben, a non-narcotic analgesic in phase II testing

Aug. 14, 1998

Pharmacokinetics of SPK-843, a promising new antifungal agent

Aug. 14, 1998

Y-700, a new kind of xanthine oxidase inhibitor in development at Yoshitomi

Aug. 14, 1998

AU-006, a novel quinoline derivative with potent antiulcer activity

Aug. 14, 1998

Known antiischemic agent demonstrates cognition-enhancing effects

Aug. 14, 1998

HMN-1152, a smooth muscle relaxant with a novel mechanism of action

Aug. 14, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...